|Mr. Gregory Hamilton||CEO & Member of the Exec. Board||N/A||N/A||1970|
|Mr. Albert Weber||Exec. VP of Fin. & Member of the Exec. Board||N/A||N/A||1963|
|Dr. Jorge A. Garces||Advisor||N/A||N/A||1972|
|Mr. Peter Vogt||VP of Corp. Communications & Investor Relations||N/A||N/A||N/A|
|Dr. Noel Thomas Doheny||Chief Exec. Officer of Epigenomics Inc.||N/A||N/A||N/A|
|Frederic Hilke||Investor Relations Officer||N/A||N/A||N/A|
Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, Asia, and internationally. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer using its proprietary DNA methylation biomarker, Septin9. The company also offers Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its development pipeline also contains products for screening, early detection, and diagnosis of cancers. In addition, the company engages in the identification of biomarker opportunities for various cancers, such as bladder cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.
Epigenomics AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.